PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
PDS Biotechnology CorporationNASDAQ: PDSB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $5.46K a year earlier. Trailing-twelve-month depreciation & amortization was $16.38K. Over 3 fiscal years it compounded at +533.2% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $4.09K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 21.84K USD
- Year-over-year change
- -63.5%
- 4-year CAGR
- +42.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.84K | -63.5% |
| FY2024 | 2024-12-31 | 59.79K | +4.3% |
| FY2023 | 2023-12-31 | 57.33K | +66558.1% |
| FY2022 | 2022-12-31 | 86 | -98.4% |
| FY2021 | 2021-12-31 | 5.36K | — |
Depreciation & Amortization vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 depreciation & amortization of $16.38K is the 5th highest of the 6 companies compared; the peer median is $821K.
- Its year-over-year change of -48.0% is the 5th highest of 6, against a peer median of -18.3%.
- Over three fiscal years its annual growth of +533.2% compares with a peer median of -0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.39M | -18.3% | -5.9% | 2.6% | |
| LTM Jun 2026 | $873K | +7.1% | +5.5% | 2.5% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $821K | -17.4% | +29.0% | — |
| LTM Mar 2026 | $108K | -98.9% | -85.2% | — | |
| LTM Mar 2026 | $16.38K | -48.0% | +533.2% | — | |
| LTM Mar 2026 | $3 | -25.0% | — | — | |
| Peer median (excluding PDSB) | $821K | -18.3% | -0.2% | 2.5% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 57.33K | 59.79K | 0 |
| Gross Profit | 0 | 0 | (57.33K) | (59.79K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
| Selling, General & Admin | 10.18M | 12.24M | 15.28M | 13.7M | 12.52M |
| Operating Expenses | 21.44M | 41.67M | 43.05M | 36.26M | 31.54M |
| Depreciation & Amortization | 5.36K | 86 | 57.33K | 59.79K | 21.84K |
| EBITDA | (21.43M) | (40.74M) | (40.09M) | (33.75M) | (30.3M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.44M) | (41.67M) | (43.05M) | (36.32M) | (31.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4.35K | 935.18K | 2.9M | 2.52M | 1.22M |
| Interest Expense | 0 | 1.32M | 4.21M | 4.67M | 5.34M |
| Other Income / Expenses | 4.35K | (381.34K) | (1.3M) | (2.16M) | (4.12M) |
| Income Before Tax | (21.43M) | (42.05M) | (44.35M) | (38.48M) | (35.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.52M) | (1.2M) | (1.41M) | (869.17K) | (1.17M) |
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| EPS (Diluted) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| Weighted Avg Shares | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
| Weighted Avg Shares (Diluted) | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.